Genomic diagnostics company Veracyte Inc (Nasdaq:VCYT) stated on Tuesday that it recorded a net loss of USD0.7m for the third quarter ended 30 September 2019.
This marks an improvement of improvement of 84% from net loss of USD4.47m the same prior year quarter.
Net loss per share of USD0.02 was recorded for the third quarter ended 30 September 2019, a rise of 83% from net loss per share of 0.12 in the comparable year quarter.
Revenue of USD31.0m was generated for the third quarter of 2019, up 32% over the revenues of USD23.4m in the third quarter of 2018.
Research and development expenses of USD3.6m and USD3.4m were announced for the third quarters of 2019 and 2018 respectively.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return